Skip to main content
. 2016 Nov 23;6:37464. doi: 10.1038/srep37464

Figure 2. Intracellular signaling causes a change of ectodomain structure that determines protease accessibility of the CD44 ectodomain.

Figure 2

(A) TPA treatment increases CD44 ectodomain trypsin sensitivity. (B) Schematic for putative trypsin sites hidden inside CD44’s three-dimensional structure. (A) Metalloprotease inhibition was used to block ADAM activity in CD44-transfected RPM-MC cells (GM6001 (15 μM)); 6 hours after TPA addition cells were probed with trypsin, lysed, and cleavage products resolved by SDS PAGE and immunoblot. γ-secretase inhibitor DAPT (5 μM) was added to all experiments. See sketch for trypsin cleavage site and tag location. Shown are one representative experiment of four independent experiments which have been evaluated by densitometry; the column diagram shows mean values of relative levels ±SD from four independent experiments.